Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
European Journal of Medical Research
Published in: European Journal of Medical Research 1/2023

Open Access 01-12-2023 | Research

m1A Regulatory gene signatures are associated with certain immune cell compositions of the tumor microenvironment and predict survival in kidney renal clear cell carcinoma

Authors: Linjun Zhou, Weidong Zhou, Yuan Li, Ruifang Hua

Published in: European Journal of Medical Research | Issue 1/2023

Login to get access

Abstract

Adenosine N1 methylation (m1A) of RNA, a type of post-transcriptional modification, has been shown to play a significant role in the progression of cancer. The objective of the current research was to analyze the genetic alteration and prognostic significance of m1A regulators in kidney renal clear cell carcinoma (KIRC). Genomic and clinicopathological characteristics were obtained from 558 KIRC patients in the Cancer Genome Atlas (TCGA) and Gene Omnibus Expression (GEO) databases. Alterations in the gene expression of ten m1A-regulators were analyzed and survival analysis was performed using the Cox regression method. We also identified three clusters of patients based on their distinct m1A alteration patterns, using integrated analysis of the ten m1A-related regulators, which were significantly related to overall survival (OS), disease-free survival (DFS) and tumor microenvironment (TME) immune cell infiltration cells in KIRC. Our findings showed that m1A alteration patterns have critical roles in determining TME complexity and its immune cell composition. Furthermore, different m1A expression patterns were significantly associated with DFS and OS rates in KIRC patients. In conclusion, the identified m1A RNA modification patterns offer a potentially effective way to classify KIRC patients based on their TME immune cell infiltration, enabling the development of more personalized and successful treatment strategies for these patients.
Appendix
Available only for authorised users
Literature
1.
2.
Pallagani L, Choudhary GR, Himanshu P, Madduri VK, Singh M, Gupta P, et al. Epidemiology and clinicopathological profile of renal cell carcinoma: a review from tertiary care referral centre. J Kidney Cancer VHL. 2021;8(1):1.PubMedPubMedCentral
3.
Tacconi EM, Tuthill M, Protheroe A. Review of adjuvant therapies in renal cell carcinoma: evidence to date. Onco Targets Ther. 2020;13:12301.PubMedPubMedCentral
4.
Lotan Y, Karam JA, Shariat SF, Gupta A, Roupret M, Bensalah K, et al. Renal-cell carcinoma risk estimates based on participants in the prostate lung colorectal, and ovarian cancer screening trial and national lung screening trial urologic oncology seminars and original investigations. Amsterdam: Elsevier; 2016.
5.
Ricketts CJ, Linehan WM. Gender specific mutation incidence and survival associations in clear cell renal cell carcinoma (CCRCC). PLoS ONE. 2015;10(10): e0140257.PubMedPubMedCentral
6.
Yin L, Li W, Wang G, Shi H, Wang K, Yang H, et al. NR1B2 suppress kidney renal clear cell carcinoma (KIRC) progression by regulation of LATS 1/2-YAP signaling. J Exp Clin Cancer Res. 2019;38(1):1–12.
7.
Hsieh JJ, Purdue MP, Signoretti S, Swanton C, Albiges L, Schmidinger M, et al. Renal cell carcinoma. Nat Rev Dis Primers. 2017;3(1):1–19.
8.
Rosenblum D, Peer D. Omics-based nanomedicine: the future of personalized oncology. Cancer Lett. 2014;352(1):126–36.PubMed
9.
Frantzi M, Hupe MC, Merseburger AS, Schanstra JP, Mischak H, Latosinska A. Omics derived biomarkers and novel drug targets for improved intervention in advanced prostate cancer. Diagnostics. 2020;10(9):658.PubMedPubMedCentral
10.
Fujiwara N, Qian T, Koneru B, Hoshida Y. Omics-derived hepatocellular carcinoma risk biomarkers for precision care of chronic liver diseases. Hepatol Res. 2020;50(7):817–30.PubMedPubMedCentral
11.
Qu Y, Feng J, Wu X, Bai L, Xu W, Zhu L, et al. A proteogenomic analysis of clear cell renal cell carcinoma in a Chinese population. Nat Commun. 2022;13(1):2052.PubMedPubMedCentral
12.
Ferro M, Crocetto F, Barone B, Del Giudice F, Maggi M, Lucarelli G, et al. Artificial intelligence and radiomics in evaluation of kidney lesions: a comprehensive literature review. Ther Adv Urol. 2023;15:17562872231164804.PubMedPubMedCentral
13.
Nachtergaele S, He C. The emerging biology of RNA post-transcriptional modifications. RNA Biol. 2017;14(2):156–63.PubMed
14.
Roundtree IA, Evans ME, Pan T, He C. Dynamic RNA modifications in gene expression regulation. Cell. 2017;169(7):1187–200.PubMedPubMedCentral
15.
Zhang C, Jia G. Reversible RNA modification N1-methyladenosine (m1A) in mRNA and tRNA. Genom Proteom Bioinform. 2018;16(3):155–61.
16.
Wang S, Sun C, Li J, Zhang E, Ma Z, Xu W, et al. Roles of RNA methylation by means of N6-methyladenosine (m6A) in human cancers. Cancer Lett. 2017;408:112–20.PubMed
17.
Zhao BS, He C. Pseudouridine in a new era of RNA modifications. Cell Res. 2015;25(2):153–4.PubMed
18.
Trixl L, Lusser A. The dynamic RNA modification 5-methylcytosine and its emerging role as an epitranscriptomic mark. Wiley Interdiscipl Rev RNA. 2019;10(1): e1510.
19.
Xie S, Chen W, Chen K, Chang Y, Yang F, Lin A, et al. Emerging roles of RNA methylation in gastrointestinal cancers. Cancer Cell Int. 2020;20(1):1–11.
20.
Dominissini D, Rechavi G. Loud and clear epitranscriptomic m1A signals: now in single-base resolution. Mol Cell. 2017;68(5):825–6.PubMed
21.
Song J, Yi C. Chemical modifications to RNA: a new layer of gene expression regulation. ACS Chem Biol. 2017;12(2):316–25.PubMed
22.
23.
Shi Q, Xue C, Yuan X, He Y, Yu Z. Gene signatures and prognostic values of m1A-related regulatory genes in hepatocellular carcinoma. Sci Rep. 2020;10(1):1–12.
24.
25.
Gao L, Chen R, Sugimoto M, Mizuta M, Kishimoto Y, Omori K. The Impact of m1A methylation modification patterns on tumor immune microenvironment and prognosis in oral squamous cell carcinoma. Int J Mol Sci. 2021;22(19):10302.PubMedPubMedCentral
26.
27.
Barbieri I, Kouzarides T. Role of RNA modifications in cancer. Nat Rev Cancer. 2020;20(6):303–22.PubMed
28.
Xiong X, Li X, Yi C. N1-methyladenosine methylome in messenger RNA and non-coding RNA. Curr Opin Chem Biol. 2018;45:179–86.PubMed
29.
30.
Chatterjee B, Shen C-KJ, Majumder P. RNA modifications and RNA metabolism in neurological disease pathogenesis. Int J Mol sci. 2021;22(21):11870.PubMedPubMedCentral
31.
Li Y, Zheng D, Wang F, Xu Y, Yu H, Zhang H. Expression of demethylase genes, FTO and ALKBH1, is associated with prognosis of gastric cancer. Dig Dis Sci. 2019;64(6):1503–13.PubMedPubMedCentral
32.
Li J, Zhang C, Yuan X, Cao Y. Molecular characteristics of N1-methyladenosine regulators and their correlation with overall cancer survival. DNA Cell Biol. 2021;40(3):513–22.PubMed
33.
34.
Wang Y, Wang J, Li X, Xiong X, Wang J, Zhou Z, et al. N1-methyladenosine methylation in tRNA drives liver tumourigenesis by regulating cholesterol metabolism. Nat Commun. 2021;12(1):1–19.
35.
Miao Y-D, Mu L-J, Tang X-L, Wang J-T, Wu J-J, Chen Y-G, et al. 2021. N1-Methyladenosine (m1A) regulator-mediated methylation modification modes and tumor microenvironment infiltration characteristics in head and neck squamous cell Carcinomas. 2021.
36.
37.
Ni Z, Xing D, Zhang T, Ding N, Xiang D, Zhao Z, et al. Tumor-infiltrating B cell is associated with the control of progression of gastric cancer. Immunol Res. 2021;69(1):43–52.PubMed
38.
39.
Qin Y, Peng F, Ai L, Mu S, Li Y, Yang C, et al. Tumor-infiltrating B cells as a favorable prognostic biomarker in breast cancer: a systematic review and meta-analysis. Cancer Cell Int. 2021;21(1):1–8.
40.
Sjöberg E, Frödin M, Lövrot J, Mezheyeuski A, Johansson M, Harmenberg U, et al. A minority-group of renal cell cancer patients with high infiltration of CD20+ B-cells is associated with poor prognosis. Br J Cancer. 2018;119(7):840–6.PubMedPubMedCentral
41.
Tessier-Cloutier B, Twa DD, Marzban M, Kalina J, Chun HJE, Pavey N, et al. The presence of tumour-infiltrating neutrophils is an independent adverse prognostic feature in clear cell renal cell carcinoma. J Pathol Clin Res. 2021;7(4):385–96.PubMedPubMedCentral
42.
Chen DS, Mellman I. Elements of cancer immunity and the cancer–immune set point. Nature. 2017;541(7637):321–30.PubMed
43.
44.
Miranda-Galvis M, Teng Y. Targeting hypoxia-driven metabolic reprogramming to constrain tumor progression and metastasis. Int J Mol Sci. 2020;21(15):5487.PubMedPubMedCentral
45.
Torsello B, De Marco S, Bombelli S, Cifola I, Morabito I, Invernizzi L, et al. High glucose induces an activated state of partial epithelial-mesenchymal transition in human primary tubular cell cultures. PLoS ONE. 2023;18(2): e0279655.PubMedPubMedCentral
46.
Bianchi C, Meregalli C, Bombelli S, Di Stefano V, Salerno F, Torsello B, et al. The glucose and lipid metabolism reprogramming is grade-dependent in clear cell renal cell carcinoma primary cultures and is targetable to modulate cell viability and proliferation. Oncotarget. 2017;8(69): 113502.PubMedPubMedCentral
47.
Ragone R, Sallustio F, Piccinonna S, Rutigliano M, Vanessa G, Palazzo S, et al. Renal cell carcinoma: a study through NMR-based metabolomics combined with transcriptomics. Diseases. 2016;4(1):7.PubMedPubMedCentral
48.
Lucarelli G, Galleggiante V, Rutigliano M, Sanguedolce F, Cagiano S, Bufo P, et al. Metabolomic profile of glycolysis and the pentose phosphate pathway identifies the central role of glucose-6-phosphate dehydrogenase in clear cell-renal cell carcinoma. Oncotarget. 2015;6(15):13371.PubMedPubMedCentral
49.
Lucarelli G, Rutigliano M, Sallustio F, Ribatti D, Giglio A, Signorile ML, et al. Integrated multi-omics characterization reveals a distinctive metabolic signature and the role of NDUFA4L2 in promoting angiogenesis, chemoresistance, and mitochondrial dysfunction in clear cell renal cell carcinoma. Aging. 2018;10(12):3957.PubMedPubMedCentral
50.
Bombelli S, Torsello B, De Marco S, Lucarelli G, Cifola I, Grasselli C, et al. 36-kDa annexin A3 isoform negatively modulates lipid storage in clear cell renal cell carcinoma cells. Am J Pathol. 2020;190(11):2317–26.PubMed
51.
Yuan JS, Chen ZS, Wang K, Zhang ZL. Holliday junction-recognition protein modulates apoptosis, cell cycle arrest and reactive oxygen species stress in human renal cell carcinoma. Oncol Rep. 2020;44(3):1246–54.PubMed
52.
Tamma R, Rutigliano M, Lucarelli G, Annese T, Ruggieri S, Cascardi E, et al. Microvascular density, macrophages, and mast cells in human clear cell renal carcinoma with and without bevacizumab treatment urologic oncology seminars and original investigations. Amsterdam: Elsevier; 2019.
53.
Netti GS, Lucarelli G, Spadaccino F, Castellano G, Gigante M, Divella C, et al. PTX3 modulates the immunoflogosis in tumor microenvironment and is a prognostic factor for patients with clear cell renal cell carcinoma. Aging. 2020;12(8):7585.PubMedPubMedCentral
54.
Lucarelli G, Rutigliano M, Ferro M, Giglio A, Intini A, Triggiano F, et al. Activation of the kynurenine pathway predicts poor outcome in patients with clear cell renal cell carcinoma urologic oncology seminars and original investigations. Amsterdam: Elsevier; 2017.
55.
Lucarelli G, Rutigliano M, Loizzo D, di Meo NA, Lasorsa F, Mastropasqua M, et al. MUC1 tissue expression and its soluble form CA15-3 identify a clear cell renal cell carcinoma with distinct metabolic profile and poor clinical outcome. Int J Mol Sci. 2022;23(22):13968.PubMedPubMedCentral
Metadata
Title
m1A Regulatory gene signatures are associated with certain immune cell compositions of the tumor microenvironment and predict survival in kidney renal clear cell carcinoma
Authors
Linjun Zhou
Weidong Zhou
Yuan Li
Ruifang Hua
Publication date
01-12-2023
Publisher
BioMed Central
Published in
European Journal of Medical Research / Issue 1/2023
Electronic ISSN: 2047-783X
DOI
https://doi.org/10.1186/s40001-023-01292-3

Other articles of this Issue 1/2023

European Journal of Medical Research 1/2023 Go to the issue

Review

Research trends and hotspots evolution of cardiac amyloidosis: a bibliometric analysis from 2000 to 2022

Research

Multi-omics analysis of DNA replication-associated primase polymerase (PRIMPOL) in pan-cancer: a potential target for prognosis and immune response

Research

Enhanced activity of the left precuneus as a predictor of visuospatial dysfunction correlates with disease activity in rheumatoid arthritis

Research

The impact of the duration of the integrated disease management program on COPD-related outcomes

Research

Assessing vaginal wall indexes in premenopausal versus postmenopausal women by transrectal linear array high-frequency probe

Research

Development and validation of a clinical prediction model for detecting coronary heart disease in middle-aged and elderly people: a diagnostic study